Teva Fourth-Quarter Earnings Slides as Generic Sales Drop

Teva Pharmaceutical Industries Ltd.’s fourth-quarter earnings fell 19 percent as generic-drug sales dropped and competition hurt the Provigil sleep-disorder pill.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.